PUBLICATION

Pharmaceutical Technology

AUTHORS

Mercedes Ortelli, Timothy Lawrence

South Africa Pharmaceuticals 2009 Pharmaceutical Technology Release

May 05, 2009

South Africa presents the healthcare industry with many opportunities. The HIV/AIDS pandemic led to the biggest government tender ever for antiretrovirals in 2008. There are also other diseases prevalent in the region such as drug-resistant tuberculosis that are not as prominent in Western markets and enable companies to create African solutions for thecontinent’s problems. South Africa has the largest economy and the most regulated pharmaceutical industry on the continent. There are two distinct healthcare markets for the 47-million population: the government and private sector, which includes approximately 7 million people. All of the major pharmaceutical companies are represented in the country, alongside strong local players, and the market is attracting strong interest from newcomers, particularly Indian generic-drug companies looking to expand outside of their home territory.

RELATED INTERVIEWS MORE INTERVIEWS

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Piramal Pharma updates GBR in its recent developments and prospects.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

RECENT PUBLICATIONS

USA Mining 2025-26 - Pre-release

USA Mining 2025-26 pre-release is a snapshot capturing insights from over 70 executives and decision-makers across the value chain and from coast to coast, sharing not only how the industry is changing, but also where it is heading next.

MORE PREVIOUSLY PUBLISHED

MACIG

"In the past, ESG may have been emphasized more heavily compared to economics, but today we see the two dimensions balancing out."

SUBSCRIBE TO OUR NEWSLETTER